Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Terminated Phase 1 Trials for Rituximab (DB00073)

Indication	Status	Phase
DBCOND0028499 (Recurrent Adult Diffuse Small Cleaved Cell Lymphoma)	Terminated	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Treatment	Lenalidomide (DB00480) Rituximab (DB00073)
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Treatment	Bendamustine (DB06769) Devimistat (DB12109) Lipoic acid (DB00166) Rituximab (DB00073)